Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
Lexeo Therapeutics Stock
Lexeo Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- R. Nolan Townsend
- Employees
- 63
- Market cap
- $215 M
- IPO
- 03/11/2023
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked…
Lexeo Therapeutics stock: price history
1D
-9.9%
1W
-17.0%
1M
-35.5%
6M
-58.9%
YTD
-72.4%
1Y
-66.6%
2Y
-66.5%
5Y
–
10Y
–
Next earnings date
Next earnings date
14/12/2026 (in 58 days)
Volatility around earnings
~25% stronger price swings than usual
Ask the agents about Lexeo Therapeutics
Analyst assessment of Lexeo Therapeutics
PRICE TARGET LOW
US$10.00
CONSENSUS
US$21.13
MEDIAN
US$20.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 23/09/2026
Lexeo Therapeutics stock metrics
P/E
-2.38
P/B
1
EV/EBITDA
-1.52
RETURN ON EQUITY
-11.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
60.4%
FLOAT SHARES
47,418,430
AVG. DAILY VOLUME (30D)
1,539,585
Insider transactions (SEC)
Bhalla Narinder Pal
Otero Jose Manuel
Townsend Richard Nolan
Townsend Richard Nolan
Otero Jose Manuel
Institutional holders
Comparable stocks
Frequently asked questions about Lexeo Therapeutics stock
What does Lexeo Therapeutics do?
Lexeo Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is R. Nolan Townsend, the company employs around 63 people.
The IPO was on 03/11/2023; the stock trades on NASDAQ under the ticker LXEO.
What do analysts say about Lexeo Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$21.13, ranging from US$10.00 to US$30.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Lexeo Therapeutics report next?
The next earnings date is 14/12/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does Lexeo Therapeutics pay a dividend?
No, Lexeo Therapeutics currently does not pay a dividend.
Which stocks are comparable to Lexeo Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lexeo Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lexeo Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.